T3D Therapeutics, Inc.

T3D Therapeutics, Inc. T3D Therapeutics' aims to develop a ground-breaking, disease-modifying, new drug for the treatment of Alzheimer’s disease and other neurodegenerative diseases.

T3D Therapeutics’ mission is to develop its lead drug product candidate, T3D-959, currently in Phase 2 clinical trials, as a potential disease-modifying medicine for the treatment of Alzheimer’s disease with the potential to slow, stop or reverse the course of the disease. The Company is also seeking to maximize the therapeutic utility of T3D-959 for the treatment of other neurodegenerative diseases, including Huntington’s disease. T3D-959 is designed as an orally-delivered, once-a-day medicine being evaluated for the treatment of Alzheimer’s disease patients with mild to moderate disease severity. The mechanism of action of T3D-959 may provide therapeutic benefit in other central nervous system (CNS) or neurodegenerative disorders via improving dysfunctional brain glucose energy and lipid metabolism which in turn, can address cerebral structural (e.g. plaques and tangles) and stress event (e.g. inflammation, oxidative stress) aberrations.

Address

68 T. W. Alexander Drive
Research Triangle Park, NC
27709

Website

Alerts

Be the first to know and let us send you an email when T3D Therapeutics, Inc. posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Shortcuts

Share

Share on Facebook Share on Twitter Share on LinkedIn
Share on Pinterest Share on Reddit Share via Email
Share on WhatsApp Share on Instagram Share on Telegram

Category